Case report: Revealing a special and rare autoimmune GFAP astrocytopathy in the spinal cord succeeding Neurobrucellosis infection

Qiang He, Junxian Liu, Zehua Zhu, Yongxiang Tang, Lili Long, Kai HuFrontiers in Immunology 2022 · DOI

TL;DR

This case report documents the first known instance of a Brucella infection triggering autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. The study highlights the critical role of FDG-PET imaging in detecting spinal cord involvement when standard MRI results are unremarkable and demonstrates the necessity of immunosuppressive therapy when an infection sparks a secondary autoimmune neurological disorder.

What Problem Does This Paper Address?

Neurobrucellosis is a severe complication of Brucellosis (a zoonotic infection) that affects the central nervous system (CNS), often presenting with poor prognosis. While various triggers for autoimmune diseases are known, the link between a Brucella infection and the subsequent development of autoimmune GFAP astrocytopathy—a rare inflammatory CNS disease—had never been reported.

Clinicians often face a diagnostic "blind spot" when a patient’s neurological symptoms persist despite successful antibiotic treatment for an underlying infection. Furthermore, standard diagnostic tools like Magnetic Resonance Imaging (MRI) sometimes fail to show lesions in the spinal cord, leaving the cause of symptoms like numbness and urinary dysfunction a mystery. This paper addresses these gaps by detailing a successful diagnostic and treatment pathway for this rare "double-hit" of infection followed by autoimmunity.

Methods

The authors conducted a clinical case study of a 42-year-old male patient. The diagnostic process involved:

  • Serological and CSF Testing: Standard tests for Brucellosis (serum agglutination and Rose Bengal Plate Test) and analysis of cerebrospinal fluid (CSF) for white cell counts, protein levels, and oligoclonal bands.
  • Antibody Assays: A cell-based immunofluorescence assay was used to detect GFAP-IgG antibodies in both the CSF and serum.
  • Multi-modal Imaging: The patient underwent head and spinal MRI, as well as Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) to identify metabolic abnormalities in the CNS.
  • Sequential Treatment: The patient was first treated with a standard antibiotic regimen (doxycycline and rifampicin), followed by a transition to immunosuppressive therapy (plasma exchange, IVIG, and high-dose corticosteroids) once the autoimmune component was identified.

Datasets

As this is a clinical case report, no large-scale datasets or benchmarks were used. The findings are based on the clinical data, imaging, and laboratory results of a single patient.

Key Insights and Ideas

  • Infection as an Autoimmune Catalyst: The authors propose that the Brucella infection caused the destruction of cell membranes, releasing intracellular GFAP into the system. This "exposure" likely caused the immune system to falsely recognize GFAP as a foreign threat, triggering the autoimmune attack on astrocytes.
  • FDG-PET vs. MRI: In this case, the spinal MRI was unremarkable, which could have led to a misdiagnosis. However, the FDG-PET scan revealed significant hypermetabolism (increased glucose uptake) at the T12 level of the spinal cord. This suggests that FDG-PET is a more sensitive tool for detecting early-stage inflammatory or infectious lesions that have not yet caused structural changes visible on an MRI.
  • The "Two-Stage" Disease Model: The patient’s recovery occurred in stages. Antibiotics resolved the fever and systemic infection, but the neurological symptoms (myelitis) only improved significantly after high-dose steroid therapy. This underscores the importance of recognizing when a disease has shifted from an active infection to an immune-mediated process.

Key Results

  • Diagnostic Markers: High titers of GFAP-IgG antibodies (1:32) were detected in the CSF, confirming the diagnosis of autoimmune GFAP astrocytopathy.
  • Quantitative Imaging: The FDG-PET scan showed a maximum standardized uptake value (SUVmax) of 6.321 in the thoracolumbar segment, which is significantly higher than the metabolic rate of a healthy spinal cord.
  • Clinical Recovery: After receiving intravenous methylprednisolone (1,000 mg for 3 days) followed by a tapered oral prednisone regimen, the patient’s numbness, weakness, and urinary difficulties markedly improved.
  • Long-term Outcome: At a six-month follow-up, the patient remained stable and continued to show symptomatic improvement while adhering to his medication.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single Case Observation: As a case report, these findings cannot be generalized to all patients with neurobrucellosis without further large-scale studies.
  • Economic Constraints: Due to the cost, a follow-up FDG-PET scan was not performed to confirm the metabolic resolution of the T12 lesion after treatment.
  • Mechanistic Uncertainty: While the link between the infection and the autoimmune response is clinically evident, the exact molecular mechanisms (e.g., molecular mimicry vs. bystander activation) remain speculative and require further experimental validation.
  • Future Research: The authors suggest that GFAP astrocytopathy should be considered in any patient with neurobrucellosis who shows persistent neurological deficits, and they advocate for the broader use of FDG-PET in MRI-negative cases.

Summary updated

Abstract

Brucellosis, a zoonosis, can cause an inflammatory response in most organs and continues to be a public health problem in some endemic areas, whereas neurobrucellosis is a morbid form of brucellosis that affects the central nervous system (CNS) with poor prognosis. Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is an autoimmune disease, and there have been no reports of a <i>Brucella</i> infection, leading to GFAP astrocytopathy. We report the case of a patient with a positive and high level of GFAP antibodies in the cerebrospinal fluid (CSF), following a <i>Brucella</i> infection. Although this patient did not show any responsible lesions in the diffusion sequence of the magnetic resonant imaging (MRI) scan, we found an evidence of thoracolumbar (T12) involvement on fluorodeoxyglucose (FDG) positron emission tomography (PET). The symptoms of spinal cord involvement were only partly relieved after initial treatment [doxycycline (0.1 g Bid) and rifampicin (0.6 g Qd) for 6 weeks]; however, they markedly improved after the subsequent immunosuppressive therapy [intravenous methylprednisolone (1,000 mg for 3 days)], followed by a 50% reduction from the preceding dose after 3 days, and subsequently, oral prednisone tablets (60 mg/day) was started, which was then gradually tapered [reduced to 10 mg/day every 1-2 weeks)]. The positive response to immunosuppressive therapy and treatment outcome strongly indicated the presence of an autoimmune neurological disease probably triggered by some infectious factors. Therefore, our findings reveal that a <i>Brucella</i> infection is one of the causes of autoimmune GFAP astrocytopathy, and when this infection is difficult to be identified by regular MRI, FDG PET can be used as a supplementary method for diagnosis and treatment.
BibTeX
@inproceedings{he2022case,
  author = {Qiang He and Junxian Liu and Zehua Zhu and Yongxiang Tang and Lili Long and Kai Hu},
  title = {{Case report: Revealing a special and rare autoimmune GFAP astrocytopathy in the spinal cord succeeding Neurobrucellosis infection}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.950522},
}
Figure